PL2694049T3 - Tapentadol do zapobiegania przechodzeniu bólu w stan przewlekły - Google Patents

Tapentadol do zapobiegania przechodzeniu bólu w stan przewlekły

Info

Publication number
PL2694049T3
PL2694049T3 PL12718064T PL12718064T PL2694049T3 PL 2694049 T3 PL2694049 T3 PL 2694049T3 PL 12718064 T PL12718064 T PL 12718064T PL 12718064 T PL12718064 T PL 12718064T PL 2694049 T3 PL2694049 T3 PL 2694049T3
Authority
PL
Poland
Prior art keywords
chronification
tapentadol
pain
preventing
preventing chronification
Prior art date
Application number
PL12718064T
Other languages
English (en)
Inventor
Klaus Schiene
Ilona STEIGERWALD
Michel Hamon
Johannes Schneider
Silvia REINARTZ
Ulrich Jahnel
Thomas Tzschentke
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2694049(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of PL2694049T3 publication Critical patent/PL2694049T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL12718064T 2011-04-05 2012-04-03 Tapentadol do zapobiegania przechodzeniu bólu w stan przewlekły PL2694049T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11002811 2011-04-05
EP11003508 2011-04-29
EP12718064.4A EP2694049B1 (en) 2011-04-05 2012-04-03 Tapentadol for preventing chronification of pain
PCT/EP2012/001472 WO2012136349A1 (en) 2011-04-05 2012-04-03 Tapentadol for preventing chronification of pain

Publications (1)

Publication Number Publication Date
PL2694049T3 true PL2694049T3 (pl) 2019-07-31

Family

ID=46025592

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12718064T PL2694049T3 (pl) 2011-04-05 2012-04-03 Tapentadol do zapobiegania przechodzeniu bólu w stan przewlekły

Country Status (13)

Country Link
US (3) US20120309841A1 (pl)
EP (2) EP2694049B1 (pl)
JP (3) JP2014510759A (pl)
CY (1) CY1121012T1 (pl)
DK (1) DK2694049T3 (pl)
ES (1) ES2703282T3 (pl)
HR (1) HRP20181998T1 (pl)
LT (1) LT2694049T (pl)
PL (1) PL2694049T3 (pl)
PT (1) PT2694049T (pl)
RS (1) RS58064B1 (pl)
SI (1) SI2694049T1 (pl)
WO (1) WO2012136349A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694049B1 (en) 2011-04-05 2018-10-31 Grünenthal GmbH Tapentadol for preventing chronification of pain
NO2701693T3 (pl) 2011-04-29 2018-01-20
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
AU2021201351B1 (en) * 2020-11-10 2022-04-21 Grünenthal GmbH Dosage form providing prolonged release of a salt of Tapentadol with L-(+)-tartaric acid

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
CA2620364A1 (en) 2005-08-26 2007-03-01 David C. Yeomans Methods for treatment of headaches by administration of oxytocin
US20090306050A1 (en) 2006-02-03 2009-12-10 Timothy Dinan Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
PL2012763T3 (pl) * 2006-04-28 2011-08-31 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
CN102065852B (zh) 2007-11-23 2015-06-17 格吕伦塔尔有限公司 他喷他多组合物
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
MX2011011442A (es) 2009-04-30 2011-11-18 Gruenenthal Gmbh Uso de compuestos de 1-fenil-3-dimetilaminopropano para tratar dolor reumatoide.
FR2970261B1 (fr) 2011-01-10 2013-05-03 IFP Energies Nouvelles Procede d'hydrotraitement de charges lourdes d'hydrocarbures avec des reacteurs permutables incluant au moins une etape de permutation progressive
EP2694049B1 (en) 2011-04-05 2018-10-31 Grünenthal GmbH Tapentadol for preventing chronification of pain

Also Published As

Publication number Publication date
US20160354324A1 (en) 2016-12-08
CY1121012T1 (el) 2019-12-11
PT2694049T (pt) 2019-02-06
US20200009083A1 (en) 2020-01-09
US10398657B2 (en) 2019-09-03
US10813891B2 (en) 2020-10-27
HRP20181998T1 (hr) 2019-01-25
LT2694049T (lt) 2018-12-27
DK2694049T3 (da) 2019-01-02
EP3449917A2 (en) 2019-03-06
JP2018048122A (ja) 2018-03-29
JP6840057B2 (ja) 2021-03-10
WO2012136349A1 (en) 2012-10-11
EP3449917A3 (en) 2019-06-05
RS58064B1 (sr) 2019-02-28
JP2019142932A (ja) 2019-08-29
EP2694049B1 (en) 2018-10-31
JP2014510759A (ja) 2014-05-01
US20120309841A1 (en) 2012-12-06
SI2694049T1 (sl) 2019-01-31
ES2703282T3 (es) 2019-03-07
EP2694049A1 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
EP2739221A4 (en) SURGICAL ANCHOR
IL230433A0 (en) Pain management methods
EP2671565A4 (en) EXTERNAL PREPARATION FOR THE SKIN
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
ZA201502595B (en) Therapeutic methods
IL232239A0 (en) Medical use
LT2694049T (lt) Tapentadolis, skirtas skausmo perėjimo į lėtinį prevencijai
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
ZA201308117B (en) Avian-based treatment
GB201107467D0 (en) Novel treatment of pain
GB201102283D0 (en) Treatment
GB201104632D0 (en) Use of medicament
GB201110895D0 (en) Therapeutic use
GB201105933D0 (en) Medical applicator
GB201110602D0 (en) Methods of treatment
GB201109737D0 (en) Methods of treatment
GB201102267D0 (en) Treatment
GB201102284D0 (en) Treatment
GB201102271D0 (en) Treatment
GB201102272D0 (en) Treatment
GB201102273D0 (en) Treatment
GB201102274D0 (en) Treatment
GB201102275D0 (en) Treatment
GB201102276D0 (en) Treatment